Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset

Abstract

This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treatment. These results do not support the use of intravenous rt-PA for stroke treatment beyond 3 hours.

Keywords

MedicineModified Rankin ScaleThrombolysisStroke (engine)PlaceboPopulationAdverse effectTissue plasminogen activatorInternal medicineAnesthesiaIschemic strokeSurgeryIschemiaMyocardial infarction

Affiliated Institutions

Related Publications

Tissue Plasminogen Activator for Acute Ischemic Stroke

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group

Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a ...

1995 New England Journal of Medicine 11503 citations

The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)

Wayne M. Clark , Gregory W. Albers , Kenneth P. Madden +1 more

Background and Purpose —The Thrombolytic Therapy in Acute Ischemic Stroke Study, which started in August of 1991, was designed to assess the efficacy and safety of intravenous r...

2000 Stroke 415 citations

Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke

The NINDS t-PA Stroke Study Group

Background and Purpose We sought to identify variables associated with intracerebral hemorrhage in patients with acute ischemic stroke who receive tissue plasminogen activator (...

1997 Stroke 870 citations

A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: ThRombEctomy And tPA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration

Rachael MacIsaac , Pooja Khatri , Martin Bendszus +35 more

Rationale Endovascular treatment has been shown to restore blood flow effectively. Second-generation medical devices such as stent retrievers are now showing overwhelming effica...

2015 International Journal of Stroke 14 citations

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

Werner Hacke , Markku Kaste , Erich Bluhmki +11 more

As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ...

2008 New England Journal of Medicine 6420 citations

Publication Info

Year: 1999
Type: article
Volume: 282
Issue: 21
Pages: 2019-2019
Citations: 1181
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1181

OpenAlex

Cite This

APA Style

                            
                                
                                    Wayne M. Clark, 
                                
                                    S. Wissman, 
                                
                                    Gregory W. Albers
                                
                                et al.
                            
                            (1999). 
                            Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. 
                            JAMA
                            , 282
                            (21)
                            , 2019-2019.
                            https://doi.org/10.1001/jama.282.21.2019
                        

Identifiers

DOI: 10.1001/jama.282.21.2019